Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry

Komatsu, Shuhei; Fuji, Shigeo; Morishima, Toshitaka; Nakata, Kayo; Miyashiro, Isao; Ishikawa, Jun

doi:10.1007/s12185-021-03150-6

Cited by 3 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…THP is a new generation of anthracycline drugs, which are mostly used in the treatment of breast cancer, ovarian cancer, cervical cancer and other malignant tumors, and also used for doxorubicin‐resistant patients 2–4 . Compared to first‐generation anthracyclines, the cardiotoxicity of THP has been significantly reduced 5 . But THP still has irreversible cardiotoxicity, which seriously affects the clinical application of THP 6 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MiR‐494‐3p aggravates pirarubicin‐induced cardiomyocyte injury by regulating MDM4/p53 signaling pathway

Huang

Zhang

Wang

et al. 2023

Environmental Toxicology

View full text Add to dashboard Cite

ObjectivePirarubicin (THP) is a widely used antitumor drug in clinical practice, but its cardiotoxicity limits its use. There is an urgent need to find drugs to alleviate the cardiotoxicity of THP. This study aimed to investigate the effect and mechanism of miR‐494‐3p on THP‐induced cardiomyocytes.MethodsTHP induced immortalized mouse cardiomyocytes HL‐1, silenced or overexpressed miR‐494‐3p. The effects of miR‐494‐3p on HL‐1 contained in THP were investigated by CCK8, flow cytometry, ROS detection, JC‐1 mitochondrial membrane potential detection, TUNEL cell apoptosis detection, RT‐qPCR, and Western blot.ResultsmiR‐494‐3p could reduce cell viability, increase oxidative damage, and promote cell apoptosis; at the same time, it inhibited the expression of MDM4, promoted the activation of p53, and promoted the expression of apoptosis‐related proteins. MiR‐494‐3p inhibitors have the opposite effect.ConclusionmiR‐494‐3p can aggravate THP damage to HL‐1, which may be achieved by downregulating MDM4 and promoting p53. miR‐494‐3p is one of the important miRNAs in THP‐induced cardiotoxicity, which provides theoretical support for its possible use as a therapeutic target for THP‐induced cardiovascular disease.

show abstract

Section: Introductionmentioning

confidence: 99%

“…anthracyclines, the cardiotoxicity of THP has been significantly reduced. 5 But THP still has irreversible cardiotoxicity, which seriously affects the clinical application of THP. 6 Currently, propylamine is the only FDA-approved cardioprotective agent.…”

mentioning

confidence: 99%

MiR‐494‐3p aggravates pirarubicin‐induced cardiomyocyte injury by regulating MDM4/p53 signaling pathway

Huang

Zhang

Wang

et al. 2023

Environmental Toxicology

View full text Add to dashboard Cite

show abstract

“…THP is a new generation of anthracycline drugs, which are mostly used in the treatment of breast cancer, ovarian cancer, cervical cancer, and other malignant tumors, and also used for doxorubicin‐resistant patients 2–4 . Compared to first‐generation anthracyclines, the cardiotoxicity of THP has been significantly reduced 5,6 . But THP still has irreversible cardiotoxicity, which seriously affects the clinical application of THP 7,8 .…”

Section: Introductionmentioning

confidence: 99%

“…anthracyclines, the cardiotoxicity of THP has been significantly reduced. 5,6 But THP still has irreversible cardiotoxicity, which seriously affects the clinical application of THP. 7,8 So far, the mechanism of THP-induced myocardial injury has not been fully elucidated, and effective methods to alleviate THP-induced cardiotoxicity are lacking.…”

mentioning

confidence: 99%

LncRNA Miat knockdown protects against pirarubicin‐induced cardiotoxicity by targeting miRNA‐129‐1‐3p

Huang

Zhang

et al. 2023

Environmental Toxicology

View full text Add to dashboard Cite

Pirarubicin (THP) is a widely used antitumor drug in clinical practice, but its cardiotoxicity limits its use. The aim of this study was to investigate the protective effect and mechanism of knockdown of lncRNA Miat in THP‐induced cardiotoxicity. The extent of damage to immortalized cardiomyocytes in mice was assessed by CCK8, TUNEL, ROS, Ca2+, RT‐qPCR, and Western blot. The relative levels of Miat in THP‐treated cardiomyocytes (HL‐1) were measured. The protective effect of Miat on THP‐treated HL‐1 was assessed. The binding relationship between lncRNA Miat and mmu‐miRNA‐129‐1‐3p was verified by a dual luciferase reporter gene assay. The protective role of Miat/miRNA‐129‐1‐3p in THP‐induced HL‐1 was explored by performing a rescue assay. THP reduced cell viability, induced apoptosis, triggered oxidative stress and calcium overload. Expression of Miat in HL‐1 was significantly elevated after THP treatment. Miat knockdown significantly alleviated the cardiotoxicity of THP. MiR‐129‐1‐3p is a direct target of Miat. Knockdown of miR‐129‐1‐3p reversed the protective effect of Miat knockdown on HL‐1. Miat knockdown can alleviate THP‐induced cardiomyocyte injury by regulating miR‐129‐1‐3p.

show abstract

Between-hospital variations in 3-year survival among patients with newly diagnosed gastric, colorectal, and lung cancer

Morishima

Okawa

Koyama

et al. 2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

Due to increases in cancer survivability, quality assessments of cancer care must include long-term outcomes. This multicenter retrospective cohort study evaluated between-hospital variations in the 3-year survival rates of patients with gastric, colorectal, and lung cancer irrespective of treatment modality. We linked cancer registry data and administrative data from patients aged 18–99 years who were diagnosed with gastric, colorectal, or lung cancer between 2013 and 2015 in Osaka Prefecture, Japan. The 3-year survival rates were adjusted for potential prognostic factors using multilevel logistic regression models. Between-hospital variations were visually evaluated using funnel plots. We analyzed 10,296 gastric cancer patients from 30 hospitals, 9276 colorectal cancer patients from 30 hospitals, and 7978 lung cancer patients from 28 hospitals. The 3-year survival rate was 70.2%, 75.2%, and 45.0% for gastric, colorectal, and lung cancer, respectively. In the funnel plots, the adjusted survival rates of gastric and colorectal cancer for all hospitals lay between the lower and upper control limits of two standard deviations of the average survival rates. However, the adjusted survival rates of lung cancer for four hospitals lay below the lower limit while that for two hospitals lay above the upper limit. Older age, men, advanced cancer stage, comorbidities, functional disability, emergency admission, current/ex-smokers, and underweight were independently associated with poorer survival. In conclusion, there were between-hospital variations in 3-year survival for lung cancer even after adjusting for case mix. Quality improvement initiatives may be needed to raise the consistency of care.

show abstract

Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry

Cited by 3 publications

References 21 publications

MiR‐494‐3p aggravates pirarubicin‐induced cardiomyocyte injury by regulating MDM4/p53 signaling pathway

MiR‐494‐3p aggravates pirarubicin‐induced cardiomyocyte injury by regulating MDM4/p53 signaling pathway

LncRNA Miat knockdown protects against pirarubicin‐induced cardiotoxicity by targeting miRNA‐129‐1‐3p

Between-hospital variations in 3-year survival among patients with newly diagnosed gastric, colorectal, and lung cancer

Contact Info

Product

Resources

About